Ascelia Pharma: SPARKLE is blurred - Redeye

The required revaluation of a certain number of patients showed a high level of variability and this intra-reader inconsistency will require a re-evaluation of all images by a new group of independent radiology readers. Ascelia plan to give a new update regarding the timelines and the financial implications by mid-September. Our updated view is a base case valuation of SEK 11 (32) and a Bull Case of SEK 28 (100), and a Bear Case of SEK 3 (9).

Länk till analysen i sin helhet: https://www.redeye.se/research/928880/ascelia-pharma-sparkle-is-blurred?utm_source=finwire&utm_medium=RSS